A cost-utility analysis of interventions for severe proliferative vitreoretinopathy ☆

摘要: Abstract PURPOSE: The purpose of this study was to report a reference case, patient preference-based, incremental, cost-utility analysis for treatments retinal detachment associated with severe proliferative vitreoretinopathy (PVR). DESIGN: Computer-based economic model utilizing data from the Medicare health insurance system in United States. METHODS: A compared vitreoretinal surgery using expanding gases and silicone oil therapy natural course PVR. applies long-term published visual Silicone Study Group, time tradeoff utility analysis, decision Markov modeling, discounting costs benefits as per Panel on Cost-Effectiveness Health Medicine. major outcome measure year 2000 States dollars quality-adjusted life-year ($/QALY) gained. RESULTS: Vitreoretinal complicated by PVR, no treatment, resulted mean gain 0.128–0.200 discounted (3% annual rate) life-years treated patient. ($/QALY gained $40,252) slightly more cost-effective than perfluoropropane (C 3 F 8 ) gas $46,926) eyes PVR without previous vitrectomy, whereas C $46,162) $62,383) vitrectomy Sensitivity $/QALY $13,347 when 10% opposite had loss $202,128 discount rate utilized initially good vision. CONCLUSIONS: incremental expense interventions is other widely accepted interventional therapies across diverse medical specialties.